SmartZyme
About SmartZyme
SmartZyme BioPharma, Inc. is a New York-based OrbiMed portfolio company that specializes in researching and developing optimized protein, enzyme, and mRNA therapeutics through directed evolution. SmartZyme’s current portfolio includes a next-generation, ultra-accurate, glucose-sensing enzyme that undergoes direct-electron transfer which has been integrated into a sensor for use in continuous glucose monitors (CGM); and a next-generation recombinant Factor VIIa protein for acute bleeding episodes. Smartzyme is currently evaluating other potential innovative drug programs for global development.YEAR FOUNDED:
2013
LEADERSHIP:
CEO: Shilo Ben Zeev
CSO: David Baram
CTO: Mark Leavitt
JOBS:
Please click here for Smartzyme Biopharma job opportunities.
PRODUCTS:
All Products
3 articles about SmartZyme
-
Carnot BioSciences, A Spin Off Of SmartZyme BioPharma, And HemoShear Therapeutics Partner To Develop Protein-Based Therapeutics For Rare Metabolic Diseases
12/4/2018
SmartZyme BioPharma Spins Off Protein Engineering Platform into Carnot BioSciences; with the New Company's Leadership Team Comprised of Former Synageva Scientists
-
WallachBeth Capital, LLC Acts as the Sole Placement Agent for SmartZyme's Ongoing Series B-1 Offering
3/14/2018
WallachBeth Capital, a leading provider of institutional execution services, is acting as the sole placement agent for SmartZyme BioPharma's Series B-1 preferred-stock round.
-
SmartZyme Adds Two Drug Development Veterans To Broaden And Strengthen Leadership Team
7/5/2017